Boan Biotech’s March Filing Shows Stable Share Base and Sufficient Public Float

Bulletin Express04-08

Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) submitted its Monthly Return on Movements in Securities for the period ending 31 March 2026, indicating no changes to its share capital structure.

Boan Biotech’s registered and issued share capital closed the month at 0.62 billion ordinary H-shares, each with a par value of RMB 1, translating to RMB 622.33 million in registered share capital. Treasury shares remained at zero, and no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity-linked instruments were reported during the month.

The company confirmed compliance with the Hong Kong Stock Exchange’s public-float rules. Pursuant to a previously granted waiver, Boan Biotech must maintain at least an 18.14 % public float—equivalent to the level at its December 2022 listing—and this threshold was met as of 31 March 2026.

Director Jiang Hua certified that all regulatory and listing-rule requirements related to any securities activities during the month were fully observed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137696225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137696225","market":"us","top_or_hot":-1,"title":"Boan Biotech’s March Filing Shows Stable Share Base and Sufficient Public Float","media":"Bulletin Express","content":"<p>Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) submitted its Monthly Return on Movements in Securities for the period ending 31 March 2026, indicating no changes to its share capital structure.</p>\n<p>Boan Biotech’s registered and issued share capital closed the month at 0.62 billion ordinary H-shares, each with a par value of RMB 1, translating to RMB 622.33 million in registered share capital. Treasury shares remained at zero, and no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity-linked instruments were reported during the month.</p>\n<p>The company confirmed compliance with the Hong Kong Stock Exchange’s public-float rules. Pursuant to a previously granted waiver, Boan Biotech must maintain at least an 18.14 % public float—equivalent to the level at its December 2022 listing—and this threshold was met as of 31 March 2026.</p>\n<p>Director Jiang Hua certified that all regulatory and listing-rule requirements related to any securities activities during the month were fully observed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boan Biotech’s March Filing Shows Stable Share Base and Sufficient Public Float</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoan Biotech’s March Filing Shows Stable Share Base and Sufficient Public Float\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) submitted its Monthly Return on Movements in Securities for the period ending 31 March 2026, indicating no changes to its share capital structure.</p>\n<p>Boan Biotech’s registered and issued share capital closed the month at 0.62 billion ordinary H-shares, each with a par value of RMB 1, translating to RMB 622.33 million in registered share capital. Treasury shares remained at zero, and no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity-linked instruments were reported during the month.</p>\n<p>The company confirmed compliance with the Hong Kong Stock Exchange’s public-float rules. Pursuant to a previously granted waiver, Boan Biotech must maintain at least an 18.14 % public float—equivalent to the level at its December 2022 listing—and this threshold was met as of 31 March 2026.</p>\n<p>Director Jiang Hua certified that all regulatory and listing-rule requirements related to any securities activities during the month were fully observed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"","article_id":"1137696225","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137696225","pubTimestamp":1775655779,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) submitted its Monthly Return on Movements in Securities for the period ending 31 March 2026, indicating no changes to its share capital structure....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06955":"博安生物"},"translate_title":"博安生物3月份备案显示稳定的股份基础和充足的公众持股量","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1},"content_text":"Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) submitted its Monthly Return on Movements in Securities for the period ending 31 March 2026, indicating no changes to its share capital structure.\nBoan Biotech’s registered and issued share capital closed the month at 0.62 billion ordinary H-shares, each with a par value of RMB 1, translating to RMB 622.33 million in registered share capital. Treasury shares remained at zero, and no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity-linked instruments were reported during the month.\nThe company confirmed compliance with the Hong Kong Stock Exchange’s public-float rules. Pursuant to a previously granted waiver, Boan Biotech must maintain at least an 18.14 % public float—equivalent to the level at its December 2022 listing—and this threshold was met as of 31 March 2026.\nDirector Jiang Hua certified that all regulatory and listing-rule requirements related to any securities activities during the month were fully observed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137696225","isCrawlerRequest":true}